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Introduction
EPIICAL is a network of excellence concerned with a wide range
of activities, including developmental research on novel disease
modifying therapies (NDMTs), with the goal of achieving HIV
remission. A central and timely theme of the network is the
establishment of a predictive in vitro and in vivo platform to
optimise the management of perinatally HIV-infected children and
to inform treatment strategies (Figure 1). The EPIICAL project is
a global collaboration of 27 international institutions, funded
through an independent grant by ViiV Healthcare. Rome, Italy,
hosted the first EPIICAL General Assembly (9–11 November 2017).
Over 70 participants from 12 countries were brought together to
discuss the updates of the first 18 months of the project, future
strategies and perspectives. The meeting, chaired by Paolo Rossi
(OPBG) and Carlo Giaquinto (Penta Foundation), included
lectures by invited speakers, roundtable discussions and oral
presentations by each work group.
This conference report captures much of the ongoing research
and the major themes discussed during the three-day meeting.
Collection of retrospective data to provide an
informative platform
The mathematical modelling of retrospective data from unique
existing cohorts of early-treated, perinatally HIV-infected children
will provide major novel insights in the EPIICAL project [1]. The
work devoted to the implementation of the clinical platform is
co-ordinated by Pablo Rojo (Hospital 12 de Octubre, Spain) and
Louise Kuhn (Columbia University), who presented an overview
on the work completed during the first 18 months of activity.
Man Chan (Medical Research Council, UK) illustrated the analysis
of the RETRO study, which included data obtained from 51
perinatally HIV-infected children from five European sites, treated
before 6 months of age. The analyses were focused on the main
factors associated with low HIV-DNA. In multivariable analysis,
lower total HIV-1 DNA was associated with younger age at
antiretroviral treatment (ART) start, longer proportion of time spent
virally suppressed and absence of viral failure/suboptimal response
to ART. This report, on behalf of the EPIICAL Consortium, has been
recently accepted for presentation at the Conference on
Retroviruses and Opportunistic Infections (CROI) 2018 [2].
Juliane Schroeter (Utrecht University) presented a first analysis
to identify determinants of different viral responses (rapid versus
slow controllers) after early ART initiation through a mathematical
modelling approach on a subgroup of HIV-infected children treated
before 6 months of age from the EPPICC cohort. This exploratory
study, albeit limited by the heterogeneity of data deriving from
different cohorts, supports the utility of a mathematical approach
to predict viral dynamics after ART initiation in HIV-infected infants.
Through the ongoing partnership between the EPIICAL and the
CHER (Children with HIV Early Antiretroviral Therapy) study groups,
a new case of HIV viral remission has been identified.
Avy Violari (Perinatal HIV Research Unit, South Africa) presented
the main new clinical and virological findings from the CHER
cohort, highlighting the case of a perinatally HIV-infected child
in viral remission for more than 9 years, previously reported at
the 2017 International AIDS Society (IAS) conference in Paris [3].
The child started ART at age 61 days and treatment was
interrupted 40 weeks later. During follow-up, virological tests
confirmed the undetectability of HIV-RNA, with a very low level
of HIV-DNA and no replication-competent virus. HIV serology by
enzyme-linked immunosorbent assay was negative, but Western
blot showed a weak reaction to Gag and p24. The unique
availability of stored or newly collected samples from this cohort
to the EPIICAL Consortium will supplement our knowledge on host
viral control after ART interruption.
Additional retrospective data on early ART perinatally HIV-infected
children from Johannesburg were illustrated by Louise Kuhn.
Studies performed in the Nevirapine Resistance Study (NEVEREST)
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cohort confirmed the well-known relationship between HIV-DNA
and timing of ART initiation. Notably, the relevance of the HIV
antibody profile as a surrogate of reservoir size has previously been
reported by Louise Kuhn and Paolo Palma in a different group
of early-treated children [4]. Viral dynamics in very early-treated
children (starting ART within 48 hours from birth) has been
investigated in the Latency and Early Neonatal Provision of
Antiretroviral Drugs Clinical Trial (LEOPARD) study.
The issue of implementing HIV diagnosis at birth in order to
provide very early treatment in HIV-infected children in low-income
countries was presented by Lynne Mofenson (Elizabeth Glaser
Pediatric AIDS Foundation) who gave an in-depth overview of the
recent literature. Dr Mofenson gave a state-of-the-art review of
the virological and clinical benefits of early treatment. Despite
considerable progress towards prevention of new paediatric HIV
infections, there still is much more to be done before mother-to-
child transmission is eliminated. Major challenges include the timing
and modality of HIV test performance and limited availability of
paediatric drug formulations. Use of diagnostic HIV nucleic acid
testing (NAT) at birth could be beneficial to enable early
identification of, and early treatment for, in utero infections. This
approach requires linkage to a healthcare system, effective
longitudinal follow-up and treatment with age-appropriate
antiretroviral (ARV) drugs. An additional major issue raised is the
pressing need to develop formulations, dosing and more safe ARV
drugs for newborns.
Development of an experimental platform to
produce new virological and immunological data
Caroline Foster (Imperial College London, UK) introduced the
CARMA study design (Child and Adolescent Reservoir
Measurements on early suppressive ART), a cross-sectional
multicentre EPIICAL sub-study, which aims to identify the factors
that influence the establishment of a low total HIV-DNA in
perinatally HIV-infected children and adolescents on suppressive
ART. The recruitment at different European sites has already started
and Louise Kuhn proposed to enlarge the study population by
including new cohorts from ‘CARMA Africa’. The virological work
group is led by Eleni Nastouli (University College London, UK)
who presented the virological questions that will be the focus in
current and future EPIICAL studies. Sarah Watters (University
College London, UK) reported on the operational programme from
the laboratory perspective. Working with the immunological team,
standard operating procedures (SOPs) on sample flow, sample
processing and international shipping have been developed.
Moreover, a database for data storage and sample tracking has
been created with the help of the PENTA (Paediatric European
Network for Treatment of AIDS) Foundation. This successful
operational strategy based on communication between working
groups will be extended to other EPIICAL studies.
Anne Genevieve Marcelin (Université Pierre et Marie Curie,
France) presented data on HIV-DNA drug resistance and defectivity
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Figure 1. The overall goals of the EPIICAL project (above) and the milestones achieved during the first 18 months of activity (below). PoC: proof of concept; NDMT: novel disease
modifying therapies
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in vertically HIV-infected children with virological suppression from
Mali.
Laura McCoy (University College London, UK) presented
preliminary tests and data on neutralising antibodies that will be
extended to the larger cohort of the CARMA study. A sub-study
of CARMA, with the aim of investigating anatomical reservoirs was
also proposed.
The immunological work group, led by Paolo Palma (OPBG) and
Savita Pahwa (University of Miami, USA) gave an overview of
the cellular HIV-specific immune response in early-treated children.
Paolo Palma focused on HIV-specific memory responses in early
ART-treates subjects. Interestingly, preliminary data from the Rome
cohort suggest that in early ART-treated children there is a
detectable frequency of HIV-specific memory B and T cells, even
though these children are seronegative as determined by standard
HIV EIA (enzyme immunoassay). However, in seronegative children,
the HIV-specific B memory response resides in IgM memory B cells,
rather than in IgG B cells as is seen in seropositive patients.
Transcriptional data deriving from sorted HIV-specific IgM memory
B cells, presented by Nicola Cotugno (OPBG) showed distinct
pathways of genes that are activated upon in vitro stimulation
with HIV peptides in seronegative patients.
Stefano Rinaldi (University of Miami, USA) integrated these data
to show the association with polyfunctional HIV-specific CD4 T
cells in the early ART population. Mark Cameron (Case Western
Reserve University) discussed preliminary analyses performed on
distinct signatures detected by RNASeq in total peripheral blood
mononuclear cells, and after deconvolution analysis in memory
T cells between early- and late-treated children (two abstracts with
these data have been accepted at CROI 2018) [5,6]. In concluding
this section, Nigel Klein (University College London, UK)
presented a next-generation sequencing approach for studying
the T cell repertoire in children and the applicability of this
methodology in the EPIICAL studies.
The selection of populations for proof-of-
concept (PoC) studies: testing NDMTs in the
most appropriate candidates
The work group led by Carlo Giaquinto (University of Padova
and PENTA Foundation) and Jintanat Ananworanich (Henry M
Jackson Foundation for the Advancement of Military Medicine,
USA) presented ongoing work to establish a predictive platform
based on PoC studies. Many potential clinical trials were discussed.
Alfredo Tagarro (Hospital 12 de Octubre, Spain) illustrated the
details of EARTH (Early Anti-Retroviral Treatment in HIV-infected
Children), a prospective, cohort study where early-treated children
from Mozambique and South Africa will be enrolled at birth and
followed for 2 years. The main aim of this study is to identify
participants more likely to benefit from NDMTs. A closer
international collaboration between countries with high HIV
prevalence and high-income country HIV-research organisations
was suggested to be crucial to build a clinical platform and perform
large clinical trials in HIV-positive children. The selection of
promising immunotherapeutic strategies through PoC studies in
early-treated population models is one of the milestones of the
project. In line with this, Jintanat Ananworanich presented a
study proposal, currently under development, on the impact of
an adjuvanted HIV-DNA vaccine with modified vaccinia Ankara
(MVA) boosting on the viral reservoir in early-treated children.
The central hypothesis of the trial is that HIVIS DNA priming and
MVA boosting will lead to a reduction in HIV reservoir markers
as a result of vaccine-induced immune responses. The regulatory
WP led by Adriana Ceci (Consorzio per Valutazioni Biologiche e
Farmacologiche, CVBF, Italy) and Maria Grazia Lain (Ariel Glaser
Foundation, Mozambique) provided support on ethical and
regulatory issues for all the ongoing studies. The work performed,
with particular attention to data sharing and material transfer
agreement, was presented in a dedicated session by Viviana
Giannuzzi (CVBF) and Francesca Rocchi (OPBG).
The lecture by Philip Goulder (University of Oxford) focused on
paediatric non-progressors and their underlying genetic, immune
and virological mechanisms. He described the role of cytotoxic T
lymphocyte (CTL) escape in immune control of HIV and the impact
of escape mutations on viral replicative capacity, illustrating the
potential of immunotherapeutic strategies for HIV remission.
Anastasios Karadimitris (Imperial College London, UK) presented
the fascinating field of chimeric antigen receptor T cell (CART)
therapy that has dramatically changed the therapeutic prospects
for B cell malignancies, illustrating potential applications in HIV
research.
Conclusions
The first EPIICAL General Assembly meeting was held in an
atmosphere of growing optimism. Many novel and exciting
proposals for HIV research studies were discussed and are described
above. The consortium aims to maintain this integrated
developmental research on NDMTs, from predictive platforms to
proof-of-concept studies, through the excellent collaborative effort
made during the first 18 months of EPIICAL, some of which is
described in this report. The emphasis on an innovative research
platform is unique and may lead to optimisation of the
management of perinatally HIV-infected children. Collectively, the
updates and the discussions from the General Assembly attest to
the benefit of nurturing an international collaborative effort on
paediatric HIV research and confirm that EPIICAL is successfully
on track.
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